DJIA 17,678.23 -40.31 -0.23%
NASDAQ 4,863.36 -13.16 -0.27%
S&P 500 2,056.15 -4.90 -0.24%
market minute promo

Emergent BioSolutions (NYSE: EBS)



company name or ticker

Emergent BioSolutions Revamps Business to Drive Earnings - Analyst Blog

Emergent BioSolutions Initiates Pivotal Study on BioThrax - Analyst Blog

Emergent BioSolutions Wins $29M Anthrax Vaccine Deal - Analyst Blog

Emergent BioSolutions Awarded $29M 5-Year Contract To Develop A Dry Formulation Of NuThrax, A Next G

Emergent BioSolutions Awarded $29M 5-Year Contract To Develop A Dry Formulation Of NuThrax, A Next Generation Anthrax Vaccine

Emergent BioSolutions, MorphoSys Tie Up on Cancer Candidate - Analyst Blog

MorphoSys And Emergent BioSolutions Sign License Agreement to Co-Develop And Commercialize Prostate

MorphoSys And Emergent BioSolutions Sign License Agreement to Co-Develop And Commercialize Prostate Cancer Drug Candidate ES414

Emergent BioSolutions, Inc. (EBS): New Analyst Report from Zacks Equity Research - Zacks Equity Rese

Emergent BioSolutions, Inc. (EBS): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report

Emergent BioSolutions Misses on Earnings, Ups Revenue View - Analyst Blog

Emergent BioSolutions' (EBS) CEO Dan Abdun-Nabi on Q2 2014 Results - Earnings Call Transcript

Emergent BioSolutions (EBS) Q2 2014 Results - Earnings Call Webcast

See More Articles...